<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01668277</url>
  </required_header>
  <id_info>
    <org_study_id>1000026525</org_study_id>
    <nct_id>NCT01668277</nct_id>
  </id_info>
  <brief_title>Effects of Saline on Circulation in Children</brief_title>
  <official_title>Effects of Hypertonic Saline on the Pulmonary Circulation in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertensive crisis is a life-threatening condition, in which the blood pressure in&#xD;
      the pulmonary artery, vein, and capillaries. Infusion of hypertonic saline solutions expand&#xD;
      the circulating volume, thus allowing more blood to flow and reducing pressure in the artery,&#xD;
      vein, and capillaries. Furthermore, infusion of hypertonic saline has been shown to reduce&#xD;
      both systemic and pulmonary vascular resistances in adults. If the pulmonary vascular&#xD;
      resistance decreases more or to the same degree as the systemic resistance, infusion of&#xD;
      hypertonic saline may prove beneficial in the treatment of pulmonary hypertensive crisis. The&#xD;
      primary objective of this study is to investigate how a clinically relevant dose of&#xD;
      hypertonic saline affects the systemic and pulmonary circulations in children undergoing&#xD;
      cardiac catheterization during general anesthesia. This study hypothesizes that an infusion&#xD;
      of hypertonic saline over 10 minutes will reduce the pulmonary vascular resistance more than&#xD;
      the systemic vascular resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Vascular Resistance Index</measure>
    <time_frame>Change from Baseline in Pulmonary Vascular Resistance Index after 1 hour</time_frame>
    <description>Pulmonary vascular resistance index, a hemodynamic measurement, will be performed during the cardiac catherization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Vascular Resistance Index</measure>
    <time_frame>Change from Baseline in Systemic Vascular Resistance Index after 1 hour</time_frame>
    <description>Systemic vascular resistance index, a hemodynamic measurement, will be performed during the cardiac catherization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>Change from Baseline in Cardiac Index after 1 hour</time_frame>
    <description>Cardiac index, a hemodynamic measurement, will be performed during the cardiac catherization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Gas</measure>
    <time_frame>Average over 1 hour</time_frame>
    <description>Effect on blood hemoglobin, plasma potassium and sodium, measured on a blood gas analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Volume</measure>
    <time_frame>Average over 1 hour</time_frame>
    <description>Effect on plasma volume calculated from the change in blood hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Natriuretic Peptide</measure>
    <time_frame>Average over 1 hour</time_frame>
    <description>Effect on atrial natriuretic peptide</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pulmonary Hypertensive Crisis</condition>
  <arm_group>
    <arm_group_label>3 ml/kg 7.2% NaCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 ml/kg 0.9% NaCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 ml/kg 0.9% NaCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7.2% NaCl</intervention_name>
    <arm_group_label>3 ml/kg 7.2% NaCl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <arm_group_label>20 ml/kg 0.9% NaCl</arm_group_label>
    <arm_group_label>3 ml/kg 0.9% NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children who have had a heart transplant and are scheduled for elective endomyocardial&#xD;
             biopsies during general anaesthesia&#xD;
&#xD;
          -  Age &gt; 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Plasma Na &lt; 130 mmol/l or &gt;150 mmol/l&#xD;
&#xD;
          -  Refusal of consent&#xD;
&#xD;
          -  An estimated pulmonary arterial pressure which is greater than or equal to 66% of&#xD;
             systemic blood pressure&#xD;
&#xD;
          -  Children with heart failure (right and/or left), i.e clinical suspicion by either a&#xD;
             cardiologist or an anesthesiologist of inability to tolerate a fluid bolus of 3 ml/kg&#xD;
             7.2% NaCl corresponding to an expansion of the circulatory volume by approximately 9%&#xD;
             (see the section on safety), which is the equivalent of infusion approximately 20&#xD;
             ml/kg 0.9% NaCl over 10 minutes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Taylor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 8, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Katherine Taylor</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Hypertensive Crisis</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Hypertonic Saline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertensive Encephalopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

